Scynexis Inc (SCYX) gains 4.31% for July 21

Equities Staff  |

Scynexis Inc (NASDAQ: SCYX) shares gained 4.31%, or $0.3 per share, to close Wednesday at $7.26. After opening the day at $7.03, shares of Scynexis fluctuated between $7.35 and $6.87. 196,860 shares traded hands a decrease from their 30 day average of 350,586. Wednesday's activity brought Scynexis’s market cap to $149,779,245.

Scynexis is headquartered in Jersey City, New Jersey..

About Scynexis Inc

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.

Visit Scynexis Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Scynexis Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Scynexis Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Market Movers

Sponsored Financial Content